Drug intelligence / Profile preview

VIP-131I-MON

Development stage: Unknown
Lead developer: West China Hospital of Sichuan University
Modality: Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides

Overview

VIP-131I-MON is an experimental radiolabeled scrambled oligonucleotide conjugated to vasoactive intestinal peptide (VIP)-polylysine. It was utilized as a negative control in preclinical studies investigating the antitumor effects of a radioiodinated antisense oligonucleotide (VIP-131I-ASON). The VIP-polylysine component is designed to facilitate delivery of the oligonucleotide to VIP receptor-positive cells. However, due to its scrambled oligonucleotide sequence, VIP-131I-MON demonstrated no significant antitumor effect compared to normal saline in HT29 tumor xenografts.

Other names: scrambled oligonucleotide conjugated to VIP-polylysine

Targets

VIPR2 (Vasoactive intestinal polypeptide receptor 2)VIPR1 (Vasoactive intestinal peptide receptor 1)

Beyond the preview

Go deeper on VIP-131I-MON.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VIP-131I-MON.

Explore the full profile